CXCR4-targeted therapy inhibits VEGF expression and chondrosarcoma angiogenesis and metastasis

Molecular Cancer Therapeutics

Volumn 12, Issue 7, 2013, Pages 1163-1170

  Sun, Xiaojuan ^a   Charbonneau, Cherie ^a   Wei, Lei ^a   Yang, Wentian ^a   Chen, Qian ^a   Terek, Richard M ^a,b  

^a BROWN UNIVERSITY   (United States)

^b PROVIDENCE VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE RECEPTOR CXCR4; PLERIXAFOR; SMALL INTERFERING RNA; VASCULOTROPIN A;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIANGIOGENIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CARTILAGE CELL; CELL HYPOXIA; CHONDROSARCOMA; CONTROLLED STUDY; DRUG MECHANISM; DRUG TARGETING; FEMALE; HUMAN; HUMAN CELL; METASTASIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TUMOR XENOGRAFT; UMBILICAL VEIN ENDOTHELIAL CELL;

EID: 84880052558     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-12-1092     Document Type: Article

References (48)

1. Damron TA, Ward WG, Stewart A. Osteosarcoma, chondrosarcoma, and Ewing's sarcoma: national cancer data base report. Clin Orthop Relat Res 2007;459:40-7. (Pubitemid 46878192)
2. Soderstrom M, Ekfors TO, Bohling TO, Teppo LH, Vuorio EI, Aro HT. No improvement in the overall survival of 194 patients with chondrosarcoma in Finland in 1971- 1990. Acta Orthop Scand 2003;74:344- 50.
3. Giuffrida AY, Burgueno JE, Koniaris LG, Gutierrez JC, Duncan R, Scully SP. Chondrosarcoma in the United States (1973 to 2003): an analysis of 2890 cases from the SEER database. J Bone Joint Surg Am 2009;91:1063-72.
4. D'Adamo DR. Appraising the current role of chemotherapy for the treatment of sarcoma. Semin Oncol 2011;38 Suppl 3:S19-S29.
5. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000;100:57-70. (Pubitemid 30046295)
6. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011;144:646-74.
7. Weidner N, Semple JP, Welch WR, Folkman J. Tumor angiogenesis and metastasis-correlation in invasive breast carcinoma. N Engl J Med 1991;324:1-8.
8. McGough RL, Aswad BI, Terek RM. Pathologic neovascularization in cartilage tumors. Clin Orthop Relat Res 2002;(397):76-82. (Pubitemid 34442018)
9. Lee FY, Mankin HJ, Fondren G, Gebhardt MC, Springfield DS, Rosenberg AE, et al. Chondrosarcoma of bone: an assessment of outcome. J Bone Joint Surg Am 1999;81:326-38. (Pubitemid 29153210)
10. McGough RL, Lin C, Meitner P, Aswad BI, Terek RM. Angiogenic cytokines in cartilage tumors. Clin Orthop Relat Res 2002;(397):62-9. (Pubitemid 34442016)
11. Berend KR, Toth AP, Harrelson JM, Layfield LJ, Hey LA, Scully SP. Association between ratio of matrix metalloproteinase-1 to tissue inhibitor of metalloproteinase-1 and local recurrence, metastasis, and survival in human chondrosarcoma. J Bone Joint Surg Am 1998;80:11-7. (Pubitemid 28087295)
12. Muller A, Homey B, Soto H, Ge N, Catron D, Buchanan ME, et al. Involvement of chemokine receptors in breast cancer metastasis. Nature 2001;410:50-6. (Pubitemid 32225831)
13. Tashiro K, Tada H, Heilker R, Shirozu M, Nakano T, Honjo T. Signal sequence trap: a cloning strategy for secreted proteins and type I membrane proteins. Science 1993;261:600-3. (Pubitemid 23278369)
14. Shirozu M, Nakano T, Inazawa J, Tashiro K, Tada H, Shinohara T, et al. Structure and chromosomal localization of the human stromal cellderived factor 1 (SDF1) gene. Genomics 1995;28:495-500.
15. Bartolome RA, Molina-Ortiz I, Samaniego R, Sanchez-Mateos P, Bustelo XR, Teixido J. Activation of Vav/Rho GTPase signaling by CXCL12 controls membrane-type matrix metalloproteinase-dependent melanoma cell invasion. Cancer Res 2006;66:248-58. (Pubitemid 43166031)
16. Rutkowski P, Kaminska J, Kowalska M, Ruka W, Steffen J. Cytokine and cytokine receptor serum levels in adult bone sarcoma patients: correlations with local tumor extent and prognosis. J Surg Oncol 2003;84:151-9. (Pubitemid 37363158)
17. Liang Z, Brooks J, Willard M, Liang K, Yoon Y, Kang S, et al. CXCR4/CXCL12 axis promotes VEGF-mediated tumor angiogenesis through Akt signaling pathway. Biochem Biophys Res Commun 2007;359:716-22. (Pubitemid 46908803)
18. Wang J, Wang J, Sun Y, Song W, Nor JE, Wang CY, et al. Diverse signaling pathways through the SDF-1/CXCR4 chemokine axis in prostate cancer cell lines leads to altered patterns of cytokine secretion and angiogenesis. Cell Signal 2005;17:1578-92. (Pubitemid 41253997)
19. Gelmini S, Mangoni M, Castiglione F, Beltrami C, Pieralli A, Andersson KL, et al. The CXCR4/CXCL12 axis in endometrial cancer. Clin Exp Metastasis 2009;26:261-8.
20. Kajiyama H, Shibata K, Terauchi M, Ino K, Nawa A, Kikkawa F. Involvement of SDF-1alpha/CXCR4 axis in the enhanced peritoneal metastasis of epithelial ovarian carcinoma. Int J Cancer 2008;122:91-9. (Pubitemid 350209982)
21. Pan J, Mestas J, Burdick MD, Phillips RJ, Thomas GV, Reckamp K, et al. Stromal derived factor-1 (SDF-1/CXCL12) and CXCR4 in renal cell carcinoma metastasis. Mol Cancer 2006;5:56.
22. Dunn LK, Mohammad KS, Fournier PG, McKenna CR, Davis HW, Niewolna M, et al. Hypoxia and TGF-beta drive breast cancer bone metastases through parallel signaling pathways in tumor cells and the bone microenvironment. PLoS One 2009;4:e6896.
23. Sun X, Wei L, Chen Q, Terek RM. CXCR4/SDF1 mediate hypoxia induced chondrosarcoma cell invasion through ERK signaling and increased MMP1 expression. Mol Cancer 2010;9:17.
24. Lai TH, Fong YC, Fu WM, Yang RS, Tang CH. Stromal cellderived factor-1 increase alphavbeta3 integrin expression and invasion in human chondrosarcoma cells. J Cell Physiol 2009;218:334-42.
25. Zagzag D, Esencay M, Mendez O, Yee H, Smirnova I, Huang Y, et al. Hypoxia- and vascular endothelial growth factor-induced stromal cell-derived factor-1alpha/CXCR4 expression in glioblastomas: one plausible explanation of Scherer's structures. Am J Pathol 2008;173:545-60.
26. Bachelder RE, Wendt MA, Mercurio AM. Vascular endothelial growth factor promotes breast carcinoma invasion in an autocrine manner by regulating the chemokine receptor CXCR4. Cancer Res 2002;62:7203-6. (Pubitemid 36025239)
27. Bridger GJ, Skerlj RT, Thornton D, Padmanabhan S, Martellucci SA, Henson GW, et al. Synthesis and structure-activity relationships of phenylenebis(methylene)-linked bis-tetraazamacrocycles that inhibit HIV replication. Effects of macrocyclic ring size and substituents on the aromatic linker. J Med Chem 1995;38:366-78.
28. De Clercq E. The AMD3100 story: the path to the discovery of a stem cell mobilizer (Mozobil). Biochem Pharmacol 2009;77:1655-64.
29. Committee on accelerating rare diseases research and orphan product development, Institute of Medicine. Discovery Research for Rare Diseases and Orphan Product Development. In: Field MJ, Boat TF, editors. Rare Diseases and Orphan Products. Washington DC: The National Academies Press; 2010. p.136-39.
30. Block JA, Inerot SE, Gitelis S, Kimura JH. Synthesis of chondrocytic keratan sulphate-containing proteoglycans by human chondrosarcoma cells in long-term cell culture. J Bone Joint Surg Am 1991;73:647-58.
31. Lin C, McGough R, Aswad B, Block JA, Terek R. Hypoxia induces HIF-1alpha and VEGF expression in chondrosarcoma cells and chondrocytes. J Orthop Res 2004;22:1175-81. (Pubitemid 39317905)
32. Asp J, Brantsing C, Lovstedt K, Benassi MS, Inerot S, Gamberi G, et al. Evaluation of p16 and Id1 status and endogenous reference genes in human chondrosarcoma by real-time PCR. Int J Oncol 2005;27:1577-82.
33. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods 2001;25:402-8. (Pubitemid 34164012)
34. Sun X, Wei L, Chen Q, Terek RM. HDAC4 represses vascular endothelial growth factor expression in chondrosarcoma by modulating RUNX2 activity. J Biol Chem 2009;284:21881-90.
35. Aherne WA, Dunhill MS. Morphometry. London, UK: Edward Arnold; 1982.
36. Busillo JM, Benovic JL. Regulation of CXCR4 signaling. Biochim Biophys Acta 2007;1768:952-63.
37. Pages G, Pouyssegur J. Transcriptional regulation of the vascular endothelial growth factor gene-a concert of activating factors. Cardiovasc Res 2005;65:564-73. (Pubitemid 40138977)
38. Zagzag D, Lukyanov Y, Lan L, Ali MA, Esencay M, Mendez O, et al. Hypoxia-inducible factor 1 and VEGF upregulate CXCR4 in glioblastoma: implications for angiogenesis and glioma cell invasion. Lab Invest 2006;86:1221-32. (Pubitemid 44789912)
39. Schioppa T, Uranchimeg B, Saccani A, Biswas SK, Doni A, Rapisarda A, et al. Regulation of the chemokine receptor CXCR4 by hypoxia. J Exp Med 2003;198:1391-402. (Pubitemid 37392484)
40. Iyer S, Acharya KR. Tying the knot: the cystine signature and molecular-recognition processes of the vascular endothelial growth factor family of angiogenic cytokines. FEBS J 2011;278:4304-22.
41. Liang Z, Wu T, Lou H, Yu X, Taichman RS, Lau SK, et al. Inhibition of breast cancer metastasis by selective synthetic polypeptide against CXCR4. Cancer Res 2004;64:4302-8. (Pubitemid 38802437)
42. Perissinotto E, Cavalloni G, Leone F, Fonsato V, Mitola S, Grignani G, et al. Involvement of chemokine receptor 4/stromal cell-derived factor 1 system during osteosarcoma tumor progression. Clin Cancer Res 2005;11:490- 7.
43. Sun YX, Schneider A, Jung Y, Wang J, Dai J, Wang J, et al. Skeletal localization and neutralization of the SDF-1(CXCL12)/CXCR4 axis blocks prostate cancer metastasis and growth in osseous sites in vivo. J Bone Miner Res 2005;20:318-29.
44. Wang Q, Diao X, Sun J, Chen Z. Regulation of VEGF, MMP-9 and metastasis by CXCR4 in a prostate cancer cell line. Cell Biol Int 2011;35:897-904.
45. De FV, Guarino V, Avilla E, Castellone MD, Salerno P, Salvatore G, et al. Biological role and potential therapeutic targeting of the chemokine receptor CXCR4 in undifferentiated thyroid cancer. Cancer Res 2007;67:11821-9.
46. Feng Y, Hu J, Ma J, Feng K, Zhang X, Yang S, et al. RNAi-mediated silencing of VEGF-C inhibits non-small cell lung cancer progression by simultaneously down-regulating the CXCR4, CCR7, VEGFR-2 and VEGFR-3-dependent axes-induced ERK, p38 and AKT signalling pathways. Eur J Cancer 2011;47:2353-63.
47. Xu L, Duda DG, di TE, Ancukiewicz M, Chung DC, Lauwers GY, et al. Direct evidence that bevacizumab, an anti-VEGF antibody, up-regulates SDF1alpha, CXCR4, CXCL6, and neuropilin 1 in tumors from patients with rectal cancer. Cancer Res 2009;69:7905-10.
48. Goel S, Duda DG, Xu L, Munn LL, Boucher Y, Fukumura D, et al. Normalization of the vasculature for treatment of cancer and other diseases. Physiol Rev 2011;91:1071-121.